CytoDyn In Damage-Control Mode (Again) With Clinical Holds For Leronlimab

Turbulence continues at CytoDyn, Inc. as executives at the company, which dismissed its CEO amidst controversy in January, tried to assure investors on 31 March about the business plan moving forward despite the US Food and Drug Administration putting two clinical holds for its lead candidate leronlimab, in both HIV and COVID-19.

Following the stock market closing on 30 March, CytoDyn announced that the FDA had placed a partial clinical hold on...